Trial Profile
A Phase 1, Single-Dose, Open-Label, Randomized, Two-Period Crossover Study to Evaluate the Relative Bioavailability of GBT440 300 mg Administered as Capsule Formulations in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Apr 2017
Price :
$35
*
At a glance
- Drugs Voxelotor (Primary)
- Indications Sickle cell anaemia
- Focus Pharmacokinetics
- Sponsors Global Blood Therapeutics
- 10 Apr 2017 Status changed from recruiting to completed.
- 08 Oct 2015 New trial record